US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

43.40

-0.0545-0.13%

Post-market: 43.34-0.0610-0.14%19:30 EDT

Volume:2K

Turnover:104.72K

Market Cap:120.53M

PE:- -

High:43.93

Open:43.78

Low:43.20

Close:43.46

52wk High:48.78

52wk Low:29.44

Shares:2.78M

Float Shares:2.78M

Volume Ratio:1.11

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Regeneron’s Pasatru granted FDA approval for FOP

Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?

Simply Wall St.

Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray

Telix outlines H1 2026 progress in radiopharmaceutical and precision medicine units

Travere Therapeutics Director Gary A. Lyons Disposes of USD 629,150 in Common Shares

Femasys announces FDA approval of FemBloc modular premarket approval application

Soccer-Sheffield United's Ex-Owners Winds up Company Which Bought Club

Guardant Health Director Tariq Musa Disposes of 116 Common Shares Worth $18,148.2

Amylyx Phase 3 data support FDA approval, says Citi

Guardant Health (GH) Back In Focus As New Approvals Put Valuation To The Test

Simply Wall St.

Genprex selects manufacturing organization for diabetes gene therapy

Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?

Simply Wall St.

Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next

Simply Wall St.

China Galaxy Securities: Laboratory Animals Are Essential for Innovative Drug R&D, High Demand for Mice and Monkeys on Two Main Tracks

Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million

Travere Therapeutics Posts Corporate Overview on Rare Kidney Disease Growth Strategy, Filspari Expansion and Pipeline Updates

LivaNova Chief Innovation Officer Ahmet Tezel Disposes of Shares Worth $435,409.36

Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)

BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/LFSC/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":43.401,"timestamp":1790971200000,"preClose":43.4555,"halted":0,"volume":2400,"hourTrading":{"tag":"盘后","latestPrice":43.34,"preClose":43.401,"latestTime":"19:30 EDT","volume":10,"amount":433.284,"timestamp":1790983803387,"change":-0.061,"changeRate":-0.001405,"amplitude":0},"delay":0,"changeRate":-0.001254156550954363,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"Market Closed","change":-0.0545,"latestTime":"10-02 16:00:00 EDT","open":43.775,"high":43.93,"low":43.195,"amount":104721.6336,"amplitude":0.016914,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":43.4555,"sharesOutstanding":2657035,"nav":43.44,"aum":120634400.4,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.34,"preClose":43.401,"latestTime":"19:30 EDT","volume":10,"amount":433.284,"timestamp":1790983803387,"change":-0.061,"changeRate":-0.001405,"amplitude":0},"volumeRatio":1.1111110185185262},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1111110185185262,"shares":2777035,"dividePrice":0,"high":43.93,"amplitude":0.016914,"preClose":43.4555,"low":43.195,"week52Low":29.4441,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":43.401,"eps":0,"divideRate":0,"volume":2400,"delay":0,"ttmEps":0,"open":43.775,"prevYearClose":36.6147,"prevWeekClose":44.4638,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":44.4638,"twentyDayClose":46.1466,"sixtyDayClose":47.375},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660287604","title":"Regeneron’s Pasatru granted FDA approval for FOP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287604","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660287604?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:20","pubTimestamp":1787232025,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration has approved Pasatru to reduce new heterotopic ossification and reduce clinician-assessed disease flare-ups i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenerons-pasatru-granted-fda-approval-for-fop-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","TECB","BMED","LABU","IEIH","SYNB","GNMX","XLVX","IYH","NVIB","PINK","MEDI","BBP","MRNY","BK4585","IDNA","LFSC","MRNX","RSPH","BK4588","GDOC","PSCH","FRTY","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660406265","title":"Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660406265","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660406265?lang=en_us&edition=fundamental","pubTime":"2026-08-20 13:34","pubTimestamp":1787204046,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics stock reacts to new SPY772 program and SKYLIGHT trial launch\nSpyre Therapeutics (SYRE) is in focus after the company launched its SPY772 combination program and began SKYLIGHT, a Phase 2 proof of concept trial in Hidradenitis Suppurativa.\nBoth efforts target dual inhibition of TL1A and IL-17A/F in moderate to severe HS. The approach uses SPY072 alongside background bimekizumab therapy for around 150 adult participants.\nSee our latest analysis for Spyre Therapeutics.\nSpyre...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-after-its-spy772-pro","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-syre/spyre-therapeutics/news/is-spyre-therapeutics-syre-fully-priced-after-its-spy772-pro","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LFSC","BK4139","SYRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660028408","title":"Glenmark Wins U.S. FDA Nod for Generic Flonase Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2660028408","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660028408?lang=en_us&edition=fundamental","pubTime":"2026-08-20 12:43","pubTimestamp":1787200984,"startTime":"0","endTime":"0","summary":"Glenmark Pharmaceuticals Limited ( ($IN:GLENMARK) ) just unveiled an announcement. Glenmark Pharmaceuticals has secured U.S. FDA approval for its F...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/glenmark-wins-u-s-fda-nod-for-generic-flonase-nasal-spray?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","SYNB","IEIH","FRTY","LABU","TBXU","BBP","BMED","NVIB","MEDI","PSCH","GDOC","IYH","GNMX","IBB","PINK","XLVX","TECB","MRNY","LFSC","IDNA","MRNX","BK4588","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479247","title":"Telix outlines H1 2026 progress in radiopharmaceutical and precision medicine units","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479247","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479247?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:29","pubTimestamp":1787182181,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals released an interim H1 2026 results presentation outlining...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-outlines-h1-2026-progress-in-radiopharmaceutical-and-precision-medicine-units?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-outlines-h1-2026-progress-in-radiopharmaceutical-and-precision-medicine-units?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IBB","IDNA","GNOM","MEDX","HTEC","XT","JDOC","FDIF","BK4585","HELX","BMED","TMAT","TLX","BK4588","LFSC","SYNB","WDNA","GNMX","PBE","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660478716","title":"Travere Therapeutics Director Gary A. Lyons Disposes of USD 629,150 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660478716","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660478716?lang=en_us&edition=fundamental","pubTime":"2026-08-20 04:05","pubTimestamp":1787169946,"startTime":"0","endTime":"0","summary":"Travere Therapeutics director Gary A. Lyons disposes of USD 629,150 in common sharesTravere Therapeutics director Gary A. Lyons sold 10,000 shares on Aug. 17-18 at about $62.53-$64.16.Sales followed o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL3ZcbDS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Travere Therapeutics Director Gary A. Lyons Disposes of USD 629,150 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660252964","title":"Femasys announces FDA approval of FemBloc modular premarket approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2660252964","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660252964?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:16","pubTimestamp":1787145413,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational no...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","MRNX","BK4082","BK4585","IDNA","BK4584","MRNY","IBB","SYNB","GDOC","BBP","IYH","GNMX","FEMY","NVIB","TECB","MEDI","LABU","XLVX","BK4588","TBXU","IEIH","BMED","PINK","PSCH","LFSC","RSPH","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660428271","title":"Soccer-Sheffield United's Ex-Owners Winds up Company Which Bought Club","url":"https://stock-news.laohu8.com/highlight/detail?id=2660428271","media":"Reuters","labels":["policyRegulatory","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660428271?lang=en_us&edition=fundamental","pubTime":"2026-08-19 20:22","pubTimestamp":1787142120,"startTime":"0","endTime":"0","summary":"Soccer-Sheffield United's ex-owners winds up company which bought clubLONDON, Aug 19 (Reuters)-Sheffield United's former owner on Wednesday won a bid to wind up the company that in 2024 bought the sec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nL1N44F0P9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EKG","GH","LFSC","BK4551","GNMX","GDOC","LU0320765992.SGD","PTH","BK4535","GNOM","BK4196","BK4588","LU0889565916.HKD","FFOX","LU0109394709.USD","HELX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660970474","title":"Guardant Health Director Tariq Musa Disposes of 116 Common Shares Worth $18,148.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2660970474","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660970474?lang=en_us&edition=fundamental","pubTime":"2026-08-19 06:15","pubTimestamp":1787091347,"startTime":"0","endTime":"0","summary":"Guardant Health director Tariq Musa disposes of 116 common shares worth $18,148.2Guardant Health director Tariq Musa sold 116 common shares on Aug. 17 at USD 156.45.The sale cut his directly held stak","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDLbdy8Tn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Director Tariq Musa Disposes of 116 Common Shares Worth $18,148.2","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4551","FFOX","GDOC","BK4585","EKG","LFSC","BK4196","GH","HELX","LU0320765992.SGD","BK4588","GNMX","LU0889565916.HKD","PTH","GNOM","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660595493","title":"Amylyx Phase 3 data support FDA approval, says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2660595493","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660595493?lang=en_us&edition=fundamental","pubTime":"2026-08-18 22:05","pubTimestamp":1787061936,"startTime":"0","endTime":"0","summary":"Citi says Amylyx’s (AMLX) avexitide showed a “highly differentiated” profile in the Phase 3 LUCIDITY study, a 78 participant, placebo-controlled tr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/amylyx-phase-3-data-support-fda-approval-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","NVIB","GNMX","MRNX","MEDI","IDNA","PINK","BK4588","SYNB","GDOC","BBP","LABU","PSCH","BMED","FRTY","TBXU","TECB","AMLX","MRNY","IYH","XLVX","LFSC","IEIH","IBB","RSPH","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660495332","title":"Guardant Health (GH) Back In Focus As New Approvals Put Valuation To The Test","url":"https://stock-news.laohu8.com/highlight/detail?id=2660495332","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660495332?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:26","pubTimestamp":1787059570,"startTime":"0","endTime":"0","summary":"Why Guardant Health Stock Is Back on Investors’ Radar\nGuardant Health (GH) moved into focus after several Q2 2026 developments, including FDA approval of an updated Guardant360 liquid biopsy test and new American Cancer Society support for its Shield colorectal cancer screening.\nThese clinical and guideline milestones arrived alongside stronger than expected Q1 results related to test volume and coverage trends. This provided investors with fresh information on how the company’s product...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-back-in-focus-as-new-approvals-put-valuat","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/guardant-health-gh-back-in-focus-as-new-approvals-put-valuat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0889565916.HKD","LFSC","GNMX","BK4535","GH","BK4196","GDOC","BK4585","EKG","FFOX","GNOM","PTH","BK4588","BK4551","LU0320765992.SGD","LU0109394709.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660461015","title":"Genprex selects manufacturing organization for diabetes gene therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2660461015","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660461015?lang=en_us&edition=fundamental","pubTime":"2026-08-18 19:10","pubTimestamp":1787051418,"startTime":"0","endTime":"0","summary":"Genprex (GNPX) has entered into a development and manufacturing agreement with a U.S. based clinical and commercial Contract Development and Manufa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genprex-selects-manufacturing-organization-for-diabetes-gene-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genprex-selects-manufacturing-organization-for-diabetes-gene-therapy-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNCR","LFSC","IBB","IBBQ","GNOM","BK4585","BK4588","TBXU","BK4139","FBT","EES","SYNB","GNPX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660489461","title":"Has Cogent Biosciences (COGT) Run Too Far After Wider Losses?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660489461","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660489461?lang=en_us&edition=fundamental","pubTime":"2026-08-17 17:23","pubTimestamp":1786958611,"startTime":"0","endTime":"0","summary":"Cogent Biosciences (COGT) recently reported second quarter 2026 results, with a net loss of US$96.41 million compared with US$73.53 million a year earlier. For the first half, net loss reached US$193.76 million versus US$145.52 million.\nSee our latest analysis for Cogent Biosciences.\nThe earnings update arrives after a very strong 1 year total shareholder return of 213.21%. The 90 day share price return of 21.38% and more recent 7 day share price decline of 8.67% suggest some momentum has...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/has-cogent-biosciences-cogt-run-too-far-after-wider-losses","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/has-cogent-biosciences-cogt-run-too-far-after-wider-losses","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LFSC","BK4505","COGT","CANC","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659366171","title":"Why Cogent Biosciences (COGT) Is Down 10.5% After Reporting Wider First-Half 2026 Losses – And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2659366171","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659366171?lang=en_us&edition=fundamental","pubTime":"2026-08-16 08:29","pubTimestamp":1786840180,"startTime":"0","endTime":"0","summary":"Cogent Biosciences, Inc. reported past earnings results for the second quarter and first half of 2026, with second-quarter net loss of US$96.41 million compared with US$73.53 million a year earlier, and six-month net loss of US$193.76 million versus US$145.52 million.\nThe widening losses highlight ongoing cost and funding pressures that may influence how investors assess the company’s progress toward its research and development goals.\nNext, we’ll examine how Cogent Biosciences’ higher net...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/why-cogent-biosciences-cogt-is-down-105-after-reporting-wide","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cogt/cogent-biosciences/news/why-cogent-biosciences-cogt-is-down-105-after-reporting-wide","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4505","CANC","LFSC","COGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108000527","title":"China Galaxy Securities: Laboratory Animals Are Essential for Innovative Drug R&D, High Demand for Mice and Monkeys on Two Main Tracks","url":"https://stock-news.laohu8.com/highlight/detail?id=1108000527","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108000527?lang=en_us&edition=fundamental","pubTime":"2026-08-14 15:38","pubTimestamp":1786693102,"startTime":"0","endTime":"0","summary":"China Galaxy Securities has released a research report stating that laboratory animals are a fundamental necessity for innovative drug research and development, with deep industry barriers. Two key...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","IBB","GDOC","BK1147","LFSC","SBIO","601881","WRND","06881","GSKH","XLVI","APXH","BIOY","PBE","BK0276","161027","BK1564","BK4588","BBP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659719596","title":"Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659719596","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659719596?lang=en_us&edition=fundamental","pubTime":"2026-08-14 07:21","pubTimestamp":1786663307,"startTime":"0","endTime":"0","summary":"Guardant Health Chief People Officer Terilyn Monroe disposes of common shares worth $7.61 millionGuardant Health Chief People Officer Terilyn J. Monroe cut her direct common stock stake to 22,979 shar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1rsYJl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Chief People Officer Terilyn Monroe Disposes of Common Shares Worth $7.61 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","LU0889565916.HKD","LU0109394709.USD","GNOM","GNMX","EKG","BK4551","LFSC","BK4535","FFOX","GH","HELX","BK4588","PTH","LU0320765992.SGD","GDOC","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659956371","title":"Travere Therapeutics Posts Corporate Overview on Rare Kidney Disease Growth Strategy, Filspari Expansion and Pipeline Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659956371","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659956371?lang=en_us&edition=fundamental","pubTime":"2026-08-14 07:14","pubTimestamp":1786662844,"startTime":"0","endTime":"0","summary":"Travere Therapeutics posts corporate overview on rare kidney disease growth strategy, FILSPARI expansion and pipeline updatesTravere outlined a growth plan centered on FILSPARI expansion in rare kidne","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL6Fb4d0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVTX","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162688","title":"LivaNova Chief Innovation Officer Ahmet Tezel Disposes of Shares Worth $435,409.36","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162688","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162688?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651503,"startTime":"0","endTime":"0","summary":"LivaNova Chief Innovation Officer Ahmet Tezel disposes of shares worth $435,409.36Ahmet Tezel, chief innovation officer at LivaNova, reported a net decrease in ordinary share holdings to 6,090 on Aug.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL3M7qWg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LivaNova Chief Innovation Officer Ahmet Tezel Disposes of Shares Worth $435,409.36","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065171311.SGD","BK4082","LU2065170008.USD","LU2065169927.USD","LIVN","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659162947","title":"Press Release: Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659162947","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659162947?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:05","pubTimestamp":1786651500,"startTime":"0","endTime":"0","summary":"clinical trial were presented at the 2026 European Hematology Association.  Annual Meeting. Data presented reinforced vispa-cel is the only. single-dose, off-the-shelf therapy to demonstrate deep and durable. responses on par with autologous CAR-T cell therapies in second-line . large B cell lymphoma . Efficacy and safety data in 2L LBCL. patients who had received a single dose of 80 million optimized vispa-cel. -- Optimized vispa-cel is defined as cells from a donor younger than 30. years old with at least two matched human leukocyte antigen  alleles. between patient and donor. The 27-patient subgroup best represents the. treatment regimen and patient population for Caribou's planned ANTLER-3. -- Caribou previously reached alignment with the U.S. Food and Drug. Administration  regarding its planned ANTLER-3 pivotal phase 3. clinical trial design, which is expected to be a randomized, control","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","IBB","NVIB","CR","CNCR","MEDX","SYNB","BK4161","LFSC","LD","CRBU","BK4195","GDOC","BK4230","CAR","GNOM","BK4539","TBXU","BK4588","ORR","BK4022","IBBQ","HYLG","PFS","BK4585","IDNA","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165757","title":"Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165757?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:40","pubTimestamp":1786635611,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS P...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-spyre-therapeutics-syre-and-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-spyre-therapeutics-syre-and-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065731478.USD","TMDX","LABU","XLV","PSIL","BK4137","LU0128526141.USD","XBI","LU2324357040.USD","LU0029874061.USD","SYRE","CMPS","BK4585","LFSC","BK4139","BK4588","BK4581","HCSG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155684243","title":"BofA Securities Boosts Targets on Chinese CXO Players as Strong Biotech Funding Fuels R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=1155684243","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155684243?lang=en_us&edition=fundamental","pubTime":"2026-08-13 12:50","pubTimestamp":1786596641,"startTime":"0","endTime":"0","summary":"BofA Securities has released a report indicating that the Chinese CXO sector is poised to benefit from robust biotech venture capital funding. The bank notes that strong financing in the first half...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2495084118.USD","IE00BPRC5H50.USD","LU1979443071.USD","LU0348766576.USD","BMED","LU2242644610.SGD","603259","LU1997244956.HKD","BK1141","LU1719994722.HKD","LU1251922891.USD","MEDI","IBRN","LU2125910500.SGD","SMCO","LU1969619763.USD","LU1997245177.USD","LU2328871848.SGD","BBC","APXH","IE00B5MMRT66.SGD","LFSC","02359","BK1576","FHLC","LU1808992512.USD","IE00B543WZ88.USD","LU0456842615.SGD","LU1934453819.USD","LU0708995583.HKD","XBIX","LU2488822045.USD","PSIL","LU0700851271.USD","IDNA","161027","CXO","LU1303224171.USD","LU0611395673.USD","LU2045819591.USD","PSCH","LU1997245094.SGD","LU0052750758.USD","BK1583","LU0320764599.SGD","BK0216","WX","LU1770034418.SGD","LU1046422090.SGD","LU0348767384.USD","SURI"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}]}}